

# Potassium Balances in Maintenance Hemodialysis

Hoon Young Choi, M.D.,  
Sung Kyu Ha, M.D.

Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Received: Feb 14, 2013

Accepted: Feb 18, 2013

Corresponding Author: Sung Kyu Ha, M.D., Ph.D.  
Department of Internal Medicine, Gangnam Severance Hospital Yonsei University College of Medicine, 146-92, Dogok-Dong, Gangnam-Gu, Seoul 135-720, Korea  
Tel: +82-2-2019-3313, Fax: +82-2-3463-3882  
E-mail: [hask1951@yuhs.ac](mailto:hask1951@yuhs.ac)

Potassium is abundant in the ICF compartment in the body and its excretion primarily depends on renal (about 90%), and to a lesser extent (about 10%) on colonic excretion. Total body potassium approximated to 50 mmol/kg body weight and 2% of total body potassium is in the ECF compartment and 98% of it in the intracellular compartment. Dyskalemia is a frequent electrolyte imbalance observed among the maintenance hemodialysis patients. In case of hyperkalemia, it is frequently "a silent and a potential life threatening electrolyte imbalance" among patients with ESRD under maintenance hemodialysis. The prevalence of hyperkalemia in maintenance HD patients was reported to be about 8.7-10%. Mortality related to the hyperkalemia has been shown to be about 3.1/1,000 patient-years and about 24% of patients with HD required emergency hemodialysis due to severe hyperkalemia. In contrast to the hyperkalemia, much less attention has been paid to the hypokalemia in hemodialysis patients because of the low prevalence under maintenance hemodialysis patients. Severe hypokalemia in the hemodialysis patients usually was resulted from low potassium intake (malnutrition), chronic diarrhea, mineralocorticoid use, and imprudent use of K-exchange resins. Recently, the numbers of the new patients with advanced chronic kidney disease undergoing maintenance hemodialysis are tremendously increasing worldwide. However, the life expectancy of these patients is still much lower than that of the general population. The causes of excess mortality in these patients seem to various, but dyskalemia is a common cause among the patients with ESRD undergoing hemodialysis.

**Key Words:** Potassium; Balance; Hemodialysis

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Introduction

The kidney plays a key role in maintaining potassium ([K]) homeostasis by excreting excess potassium. Potassium excretion primarily depends on renal (about 90%), and to a lesser extent (about 10%) on colonic excretion<sup>1)</sup>. However, non-renal excretion of [K] and dialytic [K] removal are important in regulating potassium balance in ESRD patients on hemodialysis because of markedly decreased renal excretion of potassium. Total body potassium is approximately 50 mmol/kg body weight and 2% of total body potassium is in the extracellular fluid (ECF) compartment and 98% of it in the intracellular fluid (ICF)

compartment<sup>2)</sup>. Oral [K] intake is initially absorbed in the intestine and enters portal circulation. And then, increased ECF [K] stimulates insulin release and in turn, insulin facilitates [K] entry into intracellular compartment by stimulating cell membrane  $\text{Na}^+\text{-K}^+$  ATPase<sup>3)</sup>. If it is not for the rapid shift of [K] from the ECF to ICF compartments, serum [K] increased acutely. Excretion of an oral [K] load in the kidney and colon is a relatively slow process, requiring 6-12 hours to be completed. So without rapid transcellular shift of serum [K] in the human body, we are exposed to hyperkalemic milieu for a while<sup>1)</sup>.

In cases of ESRD patient on maintenance hemodialysis, hyperkalemia seems to be primarily related to poor dietary compliance such as too much [K] intake, inadequate

dialysis due to noncompliance or vascular access problems, medications such as ACEIs, [K] sparing diuretics, non-selective beta blockers, NSAIDs, and unfractionated heparin use<sup>4</sup>). The prevalence of hyperkalemia in any given month of HD patients was reported to be about 8.7-10% depending on individual centers<sup>5</sup>). Mortality related to the hyperkalemia has been shown to be about 3.1/1,000 patient-years and mainly related to cardiac rhythm disturbances. So, it is frequently called “a silent and a potential life threatening killer” among patients with ESRD under maintenance hemodialysis<sup>6</sup>). In contrast to hyperkalemia, much less attention has been paid to the hypokalemia in hemodialysis patients because of the low prevalences under maintenance hemodialysis patients. Hypokalemia increases some risks of ventricular arrhythmias in patients with underlying cardiac diseases and a higher incidence of ventricular arrhythmias was reported to increase from 9 to 40% during HD in some studies<sup>7</sup>). Recently, the numbers of the new patient undergoing maintenance hemodialysis are tremendously increasing worldwide. The cause of excess mortality in these patients seems to be various, but dyskalemia is a common cause among the patients with ESRD undergoing hemodialysis. In this article, we are going to review [K] homeostasis in ESRD and how dyskalemia influences morbidity and mortality in maintenance hemodialysis patients.

### Potassium Homeostasis in the Body

Potassium plays various roles in the body maintenance of the resting membrane potential and neuromuscular functioning, intracellular acid-base balances, water balances, maintenance of cell volume, cell growth, DNA and protein synthesis, and enzymatic functions<sup>8</sup>). Daily [K] intake is estimated to range between 50-100 mmol, of which 90% of [K] intake is excreted by the kidney and the remainder by the colon. Complete excretion of ingested [K] can be excreted by the kidney in a 6-12 hour period<sup>1</sup>). Therefore short-term maintenance of ECF [K] concentration de-

pends on extra-renal mechanisms that can respond within a minutes. The majority of total body [K] is located in the intracellular compartment. Many factors influence the distribution of [K] in the body. The factors stimulating [K] shifts from the ECF to ICF compartments include insulin release, catecholamines, metabolic alkalosis, and anabolic state. Reverse processes happen in mineral acidosis, hyperosmolarity, non-selective beta-blockade use, and alpha-1 stimulation. Potassium is freely filtered at the glomerulus and approximately 65% of filtered load is reabsorbed in the proximal tubule. The collecting duct is the main site of the [K] secretion into the urine<sup>8</sup>). Factors affecting renal potassium excretion include; distal nephron sodium delivery, the renin-angiotensin-aldosterone system activation, vasopressin status, dietary potassium intake, acid-base status, distal nephron urine flow, and serum potassium concentration. Potassium secretion into the lumen of the distal nephron is passive and this passive movement of potassium is dependent on the concentration gradient across the luminal membrane, the lumen negative electrical gradient (primarily generated by sodium reabsorption) favoring secretion, and the luminal membrane's permeability to potassium<sup>9</sup>).

Aldosterone plays a key role in the regulation of potassium homeostasis. Aldosterone binds to the nuclear mineralocorticoid receptor within the distal tubule and the principal cells in the cortical collecting duct. At a cellular level, aldosterone opens apical [Na] channels and enhances  $\text{Na}^+\text{-K}^+$  ATPase activity on the baso-lateral membranes, resulting in an increase in [K] secretion<sup>10</sup>). The major stimuli for aldosterone secretion are angiotensinII and elevations in serum [K] level<sup>11</sup>). Aldosterone also influences extra-renal regulation of [K] secretion via increases in colonic and salivary secretion of [K]<sup>12</sup>).

### Hyperkalemia on Maintenance Hemodialysis

Hyperkalemia is defined as a serum [K] concentration greater than 5.0 mEq/L. The kidneys are primarily respon-

sible for [K] excretion in healthy adults, it is not surprising that patients with ESRD are at a high risk population for developing hyperkalemia. At any given level of kidney function, hyperkalemia is more likely to occur in patients who have concurrent medical conditions such as insulin deficiency or concurrent use of drugs to interfere with [K] secretions such as aldosterone antagonists, angiotensin II converting enzyme inhibitors, and/or angiotensin II receptor antagonists<sup>9</sup>. Patients with chronic renal failure on maintenance hemodialysis develop variety of adaptations to compensate for the decrease of renal [K] excretion. In this population, extra-renal colonic [K] excretion is a paramount importance in defending against hyperkalemia. This colonic [K] adaptation is mediated by increased colonic secretion, which is 2-3 fold higher in patients on hemodialysis than in patients with normal renal function<sup>13,14</sup>. The process of [K] adaptation is facilitated by the increase in aldosterone secretion associated with increases in serum [K] concentration. The other system defends against hyperkalemia by regulating distribution of potassium between the intracellular and extracellular compartments. Many factors influence [K] distribution between the ICF and ECF compartments. Insulin and catecholamines are major factors to regulate  $\text{Na}^+ - \text{K}^+ - \text{ATPase}$  activities over the short term period<sup>15</sup>. Insulin have a major role in potassium adaptation in end-stage renal disease (ESRD), enhancing cellular [K] uptake<sup>16,17</sup>. Prolonged fasting has been associated with hyperkalemia in dialysis patients<sup>17</sup>. Although bicarbonate alone has little or no effect on cellular [K] uptake in patients with ESRD<sup>18</sup>, it appears to facilitate insulin's effect perhaps by correction of acidemia<sup>19</sup>. Clinical data regarding the role of aldosterone in [K] handling in dialysis patients is equivocal<sup>20</sup>. However, with recent controlled trial fails to show a convincing [K]-lowering effect of fludrocortisone<sup>21</sup>. Secondary hyperparathyroidism is a common feature of ESRD patients. It appears to decrease cellular uptake of [K] via an increase of intracellular calcium, which suppress oxidative metabolism and ATP generation of cell and reduce  $\text{Na}^+ - \text{K}^+ - \text{ATPase}$  activity<sup>22</sup>.

Extracellular hypertonicity, usually seen with diabetic hyperglycemia<sup>23</sup> or hypertonic fluid administration<sup>24</sup>, causes hyperkalemia on the basis of convective [K] efflux from cells and insulin deficiency. Lastly, severe exercise<sup>25</sup> and hemolysis in the course of hemodialysis<sup>26</sup> release large amount of [K] into the ECF compartment and may cause severe hyperkalemia.

True hyperkalemias on maintenance hemodialysis occur by increased dietary [K] intake in interdialytic interval, absence of residual renal function which is the main sources of [K] removal in the normal persons, reduction in dialysis [K] clearance, hypoaldosteronism, metabolic acidosis usually seen in ESRD, hypercatabolic state, blood transfusions, abnormal colonic [K] secretion, and various drugs used in hemodialysis patients (e.g. cox 1&2 inhibitors, beta blockers, ACE inhibitors, Angiotensin Receptor blockers, potassium sparing diuretics, succinylcholine, digoxin, cyclosporine, tacrolimus, ketoconazole, potassium containing drugs)<sup>3,9,20,24,27</sup>. Chronic renal failure is the most common cause of [K] retention, especially when GFR falls toward 20% of normal. In most patients with nonoliguric chronic renal failure, mild hyperkalemia is usual<sup>28</sup>. In cases of chronic renal failure due to diabetes mellitus and tubulointerstitial diseases, hyperkalemia is more pronounced because of low circulating renin and aldosterone levels<sup>29</sup>. Many drugs used in the intensive care unit (ICU) can produce hyperkalemia by decreasing [K] excretion<sup>30</sup>. Shift of the intracellular [K] to extracellular compartment may lead to severe hyperkalemia in critically ill patients. The traditional concept was that metabolic acidosis has been implicated as a causative factor of hyperkalemia<sup>31</sup>. This paradigm has been disproved, and changes in serum [K] in relation to acid-base disorders are more complex than initially thought. The most common forms of acute metabolic acidosis in critically ill patients, diabetic ketoacidosis and lactic acidosis, are not associated with shift [K] out of cells<sup>32</sup>. Hyperkalemia seen with diabetic ketoacidosis is most likely caused by increased release of int-

racellular [K] due to the breakdown of muscle cells. Hypertonicity of the extracellular fluid causes water to exit cells, and [K] is swept out along with water. Unless renal function is not adequate to eliminate the excess [K], hyperkalemia occurs. This clinical setting may occur in patients with uncontrolled diabetes and renal insufficiency and can lead to severe hyperkalemia<sup>33</sup>. Massive tissue breakdown such as trauma, burn, and rhabdomyolysis, can lead to release of [K] into the extracellular space. If renal functions are severely impaired, hyperkalemia may develop. Drugs that impair [K] entry into cells can affect the transmembrane balance of [K].  $\beta$ -Adrenergic blockers inhibit the entry of [K] into cells and, in cases with renal failure, can accelerate development of hyperkalemia<sup>34</sup>. Succinylcholine blocks normal reentry of [K] into cells after depolarization and causes a temporary increase in serum [K]<sup>35</sup>. Digoxin, an inhibitor of cell membrane  $\text{Na}^+ \text{-K}^+ \text{-ATPase}$ , impairs [K] entry into cells, but does not cause significant hyperkalemia at usual therapeutic dose<sup>36</sup>. However, it sometimes may cause hyperkalemia with toxic doses<sup>37</sup>.

Clinical symptoms related to hyperkalemia are nonspecific and most often, asymptomatic. However, it affects cardiac and neuromuscular cells which are particularly sensitive to changes in serum [K]. In patients with mild to moderate hyperkalemia, patients usually complain of muscle weakness, fatigue, paresthesias, palpitations, and cardiac arrhythmias. As evidenced by characteristic changes in the electrocardiogram (ECG) that serve as indicators

of potential life-threatening arrhythmias, the first sign of increased serum [K] is tenting of the T wave. ECG changes may progress rapidly in conjunction with serum [K] levels. ECG changes include widening of the QRS complex, progressive development of atrioventricular conduction blocks, slow idioventricular rhythm, an ECG tracing that looks like a sine wave, ventricular fibrillation, and finally asystole<sup>38</sup>. ECG findings are not always sensitive to changes in serum [K] levels and there is no absolute level of serum [K] associated with a particular ECG abnormality. Sometimes, normal ECG findings have been described with severe hyperkalemia, and in some cases the first manifestation of cardiac changes from hyperkalemia may be ventricular fibrillation<sup>39,40</sup>. Hyperkalemia can cause neuromuscular symptoms such as paresthesias and weakness in the arms and legs, followed by a symmetrical flaccid paralysis of the extremities that ascends toward the trunk, finally involving the respiratory muscles. The cranial nerves are usually not affected by hyperkalemia<sup>1</sup>.

Regardless of the cause, the primary goal of treating hyperkalemia in HD patients is to prevent adverse cardiac arrhythmias. Therapy to lower serum [K] should be started immediately when serum [K] level is greater than 6.5 mEq/L or if the ECG changes show signs of conduction abnormalities. Treatment modalities are aimed at one of three mechanisms to prevent or decrease these complications: (1) direct antagonism of hyperkalemic effect on the cell membrane polarization, (2) movement of extracellular [K]

**Table 1.** Acute management of hyperkalemia

Treatment	Mechanism	Dosage/Comment	Onset	Duration
Calcium	Cardiac cell stabilizer	10 mL of 10% solution (calcium gluconate or calcium chloride)	Immediate	30-60 mins
Insulin (Regular)	Shifts K into cells	10 U Regular Insulin + Glucose (50 g) IV	15-30 mins	2-4 hrs
Albuterol	Shifts K into cells	10-20 mg by inhaler over 10 min	20-30 mins	2-3 hrs
Sodium bicarbonate	Shifts K into cells	In cases of acidosis	Hours	Duration of infusion
Potassium binding resin with sorbitol	Removes K from body	Oral: 15-30 g Retention enema: 30-50 g	4-6 hrs 1 hr	— —
Hemodialysis	Removes K from body	Preferred over peritoneal dialysis in acute cases	Immediate	—

into the intracellular compartment, and (3) removal of [K] from the body. Table 1 summarizes acute management of hyperkalemia<sup>41</sup>. However, in patients with hemodialysis, residual renal function is not sufficient to promote kaliuresis. If hyperkalemia is not urgent, sodium polystyrene sulfonate (Kayexalate) and calcium polystyrene sulfonate (Kalimate) can be used. At equilibrium, each gram of resin removes about 0.5 to 1 mEq of [K]. The usual dose of [K]-binding resins are 15 to 30 g orally. When given by mouth, [K]-binding resin has little effect for 4–6 hours because it must transit to the colon to be effective. When given as a retention enemas consisting of 30 to 50 g of the resin in 70% sorbitol solution, it works within 1 hour. It is important, however, that the enema should be retained for at least 30 to 60 minutes to obtain the desired therapeutic effect. Unfortunately, the combined use of sorbitol and Kayexalate can cause bowel necrosis and perforation. These complications seem to be more likely in severely immunocompromised patients or shortly after surgery<sup>42</sup>. In acute cases when serum [K] needs to be corrected rapidly, hemodialysis is a preferred mode of therapy. Hemodialysis can quickly remove 70 to 150 mEq of [K] and should be used as a gold standard treatment modality when other treatments fail<sup>43</sup>. In addition to the implementation of rapid treatment, the causes of hyperkalemia should be sought and immediately corrected, and offending drugs should be discontinued when possible. In cases of chronic hyperkalemia, dietary restriction of [K] is the mainstay of management in these patients (40–70 mEq/day). If acidosis is present, sodium bicarbonate is helpful by increasing distal nephron sodium delivery, inducing kaliuresis, and promoting intracellular potassium shift. An additional alternative is the use of [K]-binding resins such as Kayexalate or Kalimate combined with sorbitol to avoid constipation, at smaller doses given daily or every other day.

### **Hypokalemia on Maintenance Hemodialysis**

Hypokalemia is usually defined as serum [K] less than

3.5 mEq/L. Hypokalemia usually occurs as a consequence of [K] depletion due to either increased excretion or inadequate intake. However, shift of [K] in the extracellular to intracellular compartments also can cause hypokalemia. In cases of ESRD patients on hemodialysis, hypokalemia is a relatively rare event comparing to hyperkalemia. The precise prevalence of hypokalemia in maintenance HD patients is unknown but the prevalence is various among different centers<sup>5,44,45</sup>. Most hypokalemic patients are asymptomatic depending on serum [K] levels but it can be associated with mild muscle weakness to serious sudden cardiac death. The consequences of hypokalemia result to alterations in the resting membrane potential of cardiac and neuromuscular cells. The most serious and potentially fatal effects of hypokalemia are related to disturbances in cardiac rhythm that can lead to cardiac arrest. However, cardiac arrest caused by hypokalemia occurs almost exclusively in patients with underlying cardiac disease or patients taking digitalis. Characteristic electrocardiographic (ECG) changes associated with hypokalemia include broad, flat T waves, ST depression, the appearance of U waves, QT interval prolongation, and finally ventricular arrhythmias leading to cardiac arrest<sup>46</sup>. When serum [K] is less than 3.0 mEq/L, generalized weakness can develop and serum [K] decreases to less than 2.5 mEq/L, muscle necrosis and rhabdomyolysis can occur. With progression of hypokalemia, an ascending muscle paralysis develops, leading to respiratory failure and arrest<sup>5,8</sup>. Hypokalemia in maintenance hemodialysis patients is less frequent condition compared to hyperkalemia (0.3–0.5% Vs. 8.7–10%)<sup>5</sup> and can be caused by low dietary potassium intake, malnutrition, chronic diarrhea, prescription of drugs that can increase colonic [K] excretions such as mineralocorticoids and imprudent use of [K]-exchange resins<sup>8,45</sup>. One recent study conducted on Non Dialysis Dependent (NDD)-CKD population, overall mortality was significantly associated with both higher and lower serum potassium levels even after adjustments for relevant confounders. They also

found that hypokalemias were significantly associated with faster loss of kidney function over time, even after adjusting for other known risk factors such as BP, proteinuria and comorbid conditions. They concluded that hypo- and hyper-kalemia are associated with higher mortality in NDD-CKD patients<sup>47)</sup>.

The goal of treatment in hypokalemia on maintenance hemodialysis is to prevent cardiac rhythm disturbances and serious neuromuscular weaknesses. Supplementation of [K] is the main treatment for hypokalemia and is usually achieved with the oral administration of potassium preparations. There are four types of potassium preparations: potassium chloride, potassium phosphate, potassium bicarbonate and potassium citrate. Potassium phosphate is used to treat hypokalemia with hypophosphatemia. Potassium bicarbonate or citrate is preferred in patients with hypokalemia and metabolic acidosis. In all other settings, potassium chloride should be used. Conditions requiring emergent therapy are usually rare. In general, plasma [K] decreases by approximately 0.3 mEq/L for each 100 mEq decrease in total body [K]. Potassium replacement should be given orally except when severe hypokalemia is associated with respiratory or cardiac instability, in which case the IV route is preferred. When given intravenously, the rate of [K] administration should not exceed 20 mmol/hour to minimize possible iatrogenic hyperkalemia. For IV infusion of [K], an infusion pump and continuous cardiac monitoring are mandatory. When potas-

sium is administered intravenously through a peripheral vein, the concentrations should not exceed 50 mmol/l. IV fluids containing higher [K] concentration are often painful and cause peripheral vein irritation. Serum [K] level should be followed closely, especially when using IV route or higher doses, to prevent the development of hyperkalemia because ESRD patients with MHD have no residual renal function to excrete excess potassium<sup>48)</sup>. Table 2 shows summaries of the treatment of hypokalemia<sup>3)</sup>.

## Conclusion

Dyskalemia is a frequent electrolyte imbalance observed among the maintenance hemodialysis patients. In case of hyperkalemia, it is frequently “a silent and a potential life threatening electrolyte imbalance” among patients with ESRD under maintenance hemodialysis. The prevalence of hyperkalemia in HD patients was reported to be about 8.7-10%. Mortality related to hyperkalemia has been shown to be about 2-5% of deaths among patients with ESRD<sup>5)</sup> and about 24% of patients with HD required emergency hemodialysis due to severe hyperkalemia<sup>1)</sup>. In contrast to the hyperkalemia, hypokalemia in maintenance hemodialysis patients is less frequent condition. The precise prevalence of hypokalemia in maintenance HD patients is unknown but the prevalence is various among different centers<sup>5,44,45)</sup>. Most hypokalemic patients are asymptomatic depending on serum [K] levels but it can be associated with mild muscle weakness to serious sudden cardiac death. It can be caused by low dietary potassium intake, malnutrition, chronic diarrhea, prescription of drugs that can increase colonic [K] excretions such as mineralocorticoids and [K]-exchange resins<sup>8,45)</sup>. Much less attention has been paid to the hypokalemia in hemodialysis patients because of the low prevalence under maintenance hemodialysis patients. However, in cases of severe hypokalemia, we also pay attention to prevent cardiac rhythm disturbances and serious neuromuscular weaknesses.

**Table 2.** Treatment of hypokalemia

IV KCl :	Maximum rate, 20 mEq/hr with cardiac monitoring
	Reassess serum [K] concentration after 60 mEq infusion
	IV administration should be used cautiously in cases of;
	Cardiac arrhythmia with rapid ventricular response
	Cardiac arrhythmia due to digoxin toxicity
	Severe diarrhea
	Severe myopathy with muscle necrosis
	Paralysis
Oral KCl:	20-80 mEq/day in divided doses
	All other settings except renal tubular acidosis
	In cases of renal tubular acidosis, Oral KHCO <sub>3</sub> or K-Citrate will be used.

## Conflicts of Interest

The authors have nothing to disclose.

## References

1. Putcha N & Allon M: Management of Hyperkalemia in Dialysis Patients. *Semin Dial* 20:431-439, 2007
2. Greenberg A: Hyperkalemia: Treatment options. *Semin Nephrol* 18:46-57, 1998
3. Gennari FJ.: Disorders of potassium homeostasis: Hypokalemia and Hyperkalemia. *Crit Care Clin* 18:273-288, 2002
4. Khedr E, Abdelwhab S, El-Sharkay M, Ali M, El Said K: Prevalence of hyperkalemia among hemodialysis patients in Egypt. *Renal Failure* 31:891-898, 2009
5. Tzamaloukas AH, Avasthi PS: Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. *Am J Nephrol* 7:101-109, 1987
6. Weiner ID, Wingo CS: Hyperkalemia: A Potential Silent Killer. *J Am Soc Nephrol* 9:1535-1543, 1998
7. Abe S, Yoshizawa M, Nakanishi N, et al.: Electrocardiographic abnormalities in patients receiving hemodialysis. *Am Heart J* 131:1137-1144, 1996
8. Hoskote SS, Joshi SR, Ghosh AK: Disorders of potassium homeostasis: Pathophysiology and management. *JAPI* 56: 685-725, 2008
9. Evans KJ, Greenberg A: Hyperkalemia: A Review. *J Intensive Care Med* 20:272-290, 2005
10. Palmer LG, Frindt G: Aldosterone and potassium secretion by the cortical collecting duct. *Kidney Int* 57:1324-1328, 2000
11. Young DB, Smith MJ Jr, Jackson TE, Scott RE: Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. *Am J Physiol* 247:E328-E345, 1984
12. Basti C, Hayslett J: The cellular action of aldosterone in target epithelia. *KidneyInt* 42:250, 1992
13. Martin RS, Panese S, Virginillo M, et al.: Increased secretion of potassium in the rectum of man with chronic renal failure. *Am J Kidney Dis* 8:105-110, 1986
14. Sandle GI, Tapster S, Goodship TH: Evidence for large intestinal control of potassium homeostasis in uremic patients undergoing long-term dialysis. *ClinSci (Colch)* 73: 247-252, 1987
15. Clausen T, Everts ME: Regulation of the Na-K-pump in skeletal muscle. *KidneyInt* 35:1-13, 1989
16. Allon M, Dansby L, Shanklin N: Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. *Am J Med* 94:475-482, 1993
17. Allon M, Takeshian A, Shanklin N: Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. *Kidney Int* 43:212-217, 1993
18. Blumberg A, Weidmann P, Ferrari P: Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. *Kidney Int* 41:369-374, 1992
19. Kim HJ: Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. *Nephron* 72:476-482, 1996
20. Ahmed J, Weisberg LS: Hyperkalemia in dialysis patients. *Semin Dial* 14:348-356, 2001
21. Kaiser MO, Wiggins KJ, Sturtevant JM, et al.: A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. *Am J Kidney Dis* 47:809-814, 2006
22. Massry SG: Renal failure, parathyroid hormone and extrarenal disposal of potassium. *Miner Electrolyte Metab* 16:77-81, 1990
23. Goldfarb S, Cox M, Singer I, Goldberg M: Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. *Ann Intern Med* 84:426-432, 1976
24. Moreno M, Murphy C, Goldsmith C: Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. *J Lab Clin Med* 73: 291-298, 1969
25. Clark BA, Shannon C, Brown RS, Gervino EV: Extrarenal potassium homeostasis with maximal exercise in end-stage renal disease. *J Am Soc Nephrol* 7:1223-1227, 1996
26. Sweet SJ, McCarthy S, Steingart R, Callahan T: Hemolytic reactions mechanically induced by kinked hemodialysis lines. *Am J Kidney Dis* 27:262-266, 1996
27. Kim HJ: Pathogenesis and treatment of dyskalemia in maintenance hemodialysis and CAPD. *Electrolyte & Blood Pressure* 4:47-52, 2006
28. Kupin WL, and Narins RG: The hyperkalemia of renal failure: Pathophysiology, diagnosis and therapy. *Contrib Nephrol* 102:1-22, 1993
29. DeFronzo RA: Hyperkalemia and hyporeninemic hypopar-

- dosteronism. *Kidney Int* 17:118-134, 1980
30. Buckley MS, Leblanc JM, Cawley MJ: Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. *Crit Care Med* 38:S253-S264, 2010
  31. Burnell JM, Scribner BH, Uyeno BT, Villamil MF: The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. *J Clin Invest* 35:935-939, 1956
  32. Adroque HJ, Madias NE: Changes in plasma potassium concentration during acute acid-base disturbances. *Am J Med* 71:456-467, 1981
  33. Goldfarb S, Cox M, Singer I, Goldberg M: Acute hyperkalemia induced by hyperglycemia: Hormonal mechanisms. *Ann Intern Med* 84:426-432, 1976
  34. Arrizabalaga P, Montoliu J, Martinez Veja A: Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: Absence of mediation by insulin or aldosterone. *Proc Eur Dial Transplant Assoc* 20:572-576, 1983
  35. Gronert GA: Succinylcholine-induced hyperkalemia and beyond. *1975 Anesthesiology* 111:1372-1377, 2009
  36. Josephson GW: Digoxin intoxication and hyperkalemia. *JAMA* 244:1557-1558, 1980
  37. Rees SM, Nelson LN: Digoxin, hyperkalemia, and kidney failure. *Ann Emerg Med* 29:694-695, 1997
  38. Parham WA, Mehdiraz AA, Biermann KM, Freman CS: Hyperkalemia Revisited. *Tex Heart Inst J* 33:40-47, 2006
  39. Szerlip HM, Weiss J, Singer I: Profound hyperkalemia without electrocardiographic manifestations. *Am J Kidney Dis* 7:461-465, 1986
  40. Dodge HT, Grant RP, Seavey PW: The effect of induced hyperkalemia on the normal and abnormal electrocardiogram. *Am Heart J* 45:725-740, 1953
  41. Weisberg LS: Management of severe hyperkalemia. *Crit Care Med* 36:3246-3251, 2008
  42. Sterns RH, Rojas M, Bernstein P, Chennupati S: Ion-Exchange Resins for the Treatment of Hyperkalemia: Are they Safe and Effective *J Am Soc Nephrol* 21:733-735, 2010
  43. Musso CG: Potassium metabolism in patients with chronic kidney disease. Part II: Patients on dialysis (stage 5). *Int Urol Nephrol* 36:469-472, 2004
  44. Hwang SH, Kim HJ: Distribution of serum potassium concentration and analysis of associated factors with hyperkalemia in chronic hemodialysis patients. *Kor J Med* 50(1):87-93, 1996
  45. Hwang J-C, Wang C-T, Chen C-A, Chen H-C: Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients. *Blood Purif* 32:254-261, 2011
  46. Podrid PJ: Potassium and ventricular arrhythmias. *Am J Cardiol* 65:33E-44E, 1990
  47. Hayes J, Kalantar-Jadeh K JL, Lu JL, Turvan S, Anderson JE, Kovesdy CP: Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: The icularrole entrof race. *Nephron Clin Practi* 120:c8-c16, 2012
  48. Gennari FJ: Hypokalemia. *New Engl J Med* 339:451-458, 1998